Heiko Henze

This inventor holds 15 USPTO granted patents and 3 published patent applications, plus 7 CIPO patents and 9 EPO patents, primarily in Peptidomimetics Research. Top assignees: Polyphor Ltd., Unversität Zürich, Universitaet Zuerich. Active years: 2010-2022.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Heiko Henze. Retrieved from https://idiyas.com/inventor/heiko-henze

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 15 (Patent Applications = 3)

% Patents Active = 66.7

CIPO Patents = 7

EPO Patents = 9 (Patent Applications = 7)

Average Co-Inventor Count = 10.0

ph-index = 6

Forward Citations = 72(Granted Patents)

Location History:

Zürich, CH (2010 - 2016)
Zurich, CH (2013 - 2022)

Company Filing History:

where one patent can have more than one assignee

Years Active: 2010-2022

Loading Chart...

Areas of Expertise:

Peptidomimetics

Beta-Hairpin

Protease Inhibitors

CXCR4 Antagonists

Template-Fixed

Molecular Design

Biochemical Applications

Drug Development

15 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11421001 - Template-fixed peptidomimetics (2022-08-23),

2. 10787486 - Template-fixed peptidomimetics (2020-09-29),

3. 10562933 - Template-fixed beta-hairpin peptidomimetics with protease inhibitory activity (2020-02-18),

4. 10144765 - Template-fixed peptidomimetics (2018-12-04),

5. 10100084 - Template-fixed beta-hairpin peptidomimetics with protease inhibitory activity (2018-10-16),

6. 10000535 - Template-fixed peptidomimetics (2018-06-19),

7. 9879047 - Template-fixed peptidomimetics (2018-01-30),

8. 9556234 - Template-fixed peptidomimetics (2017-01-31),

9. 9518092 - Template-fixed beta-hairpin peptidomimetics with CXCR4 antagonizing activity (2016-12-13),

10. 8921325 - Template-fixed peptidomimetics (2014-12-30),

11. 8895695 - Template-fixed beta-hairpin peptidomimetics with CXCR4 antagonizing activity (2014-11-25),

12. 8658604 - Template-fixed beta-hairpin peptidomimetics with protease inhibitory activity (2014-02-25),

13. 8633163 - Template-fixed peptidomimetics (2014-01-21),

14. 8399611 - Template-fixed peptidomimetics (2013-03-19),

15. 7786078 - Template-fixed δ-hairpin peptidomimetics with CXCR4 antagonizing activity (2010-08-31),

Title: Heiko Henze: Innovating in Peptidomimetics

Introduction

Heiko Henze, an accomplished inventor located in Zurich, Switzerland, has made significant contributions to the field of medicinal chemistry. With a remarkable portfolio of 15 patents, Henze's work focuses on developing innovative solutions with potential applications in cancer treatment.

Latest Patents

His latest inventions include a series of template-fixed peptidomimetics, specifically Cyclo(-Tyr-His-X-Cys-Ser-Ala-Pro-Dab-Arg-Tyr-Cys-Tyr-Gln-Lys-Pro-Pro). These compounds feature a disulfide bond between Cys4 and Cys11, and pharmaceutically acceptable salts thereof. Notably, with X being either Ala or Tyr, these peptidomimetics demonstrate CXCR4 antagonizing properties, offering promising avenues for treating cancers mediated by CXCR4 receptor activity.

Career Highlights

Throughout his career, Heiko Henze has worked with renowned organizations such as Polyphor Ltd. and Universität Zürich, where he has continued to advance his research and development in the field of peptides and medicinal applications. His innovative spirit and dedication to science have earned him respect among peers and the scientific community at large.

Collaborations

Henze has collaborated with notable professionals in his field, including Frank Gombert and Daniel Obrecht. Together, they have shared knowledge and expertise to drive advancements in their research projects, emphasizing the importance of teamwork in achieving scientific breakthroughs.

Conclusion

Heiko Henze's contributions to the field of peptidomimetics underscore his role as a leading inventor in medicinal chemistry. His innovative patents not only illustrate his ability to push the boundaries of science but also highlight his commitment to developing therapeutic solutions that may one day improve cancer treatment. As he continues to innovate, the impact of his work will resonate within both academic and commercial sectors.

Profile summary based on public USPTO records.